New pain block could replace epidurals in pancreatic surgery

NCT ID NCT06411795

Recruiting now Symptom relief Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a rectus sheath block using long-acting liposomal bupivacaine can control pain as well as the standard thoracic epidural after pancreatic surgery. About 78 adults undergoing open pancreaticoduodenectomy will be randomly assigned to one of the two methods. The goal is to see if the new block reduces opioid use and avoids the low blood pressure risk linked to epidurals.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Liposomal bupivacaine
What this could lead to: If it works, this could offer a safer, equally effective pain control option after pancreatic surgery, reducing the risk of low blood pressure from epidurals.
What could go wrong: This is a small, early-phase trial (78 people) testing non-inferiority, so it may not prove the new block is truly as good. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUODENAL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

duodenum cancer pancreatic neoplasm tumor of duodenum

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUODENAL NEOPLASM PANCREATIC NEOPLASM

Contacts and locations

Locations

University of Minnesota/Masonic Cancer Center
RECRUITING

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.